287 related articles for article (PubMed ID: 32823148)
1. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.
De Angelis M; Petracca M; Lanzillo R; Brescia Morra V; Moccia M
Mult Scler Relat Disord; 2020 Oct; 45():102452. PubMed ID: 32823148
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Dersch R; Wehrum T; Fähndrich S; Engelhardt M; Rauer S; Berger B
Mult Scler; 2020 Sep; 26(10):1264-1266. PubMed ID: 32762488
[TBL] [Abstract][Full Text] [Related]
3. Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.
Möhn N; Pul R; Kleinschnitz C; Prüss H; Witte T; Stangel M; Skripuletz T
Front Immunol; 2020; 11():1059. PubMed ID: 32477373
[TBL] [Abstract][Full Text] [Related]
4. Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.
Chiarini M; Paghera S; Moratto D; Rossi N; Giacomelli M; Badolato R; Capra R; Imberti L
J Neuroimmunol; 2020 Aug; 345():577282. PubMed ID: 32505908
[TBL] [Abstract][Full Text] [Related]
5. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
6. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Baker D; Amor S; Kang AS; Schmierer K; Giovannoni G
Mult Scler Relat Disord; 2020 Aug; 43():102174. PubMed ID: 32464584
[TBL] [Abstract][Full Text] [Related]
7. MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine.
Seferoğlu M; Ethemoğlu Ö; Turan ÖF; Siva A
Neurol Sci; 2021 Sep; 42(9):3533-3535. PubMed ID: 34165650
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab.
Fernández-Díaz E; Gracia-Gil J; García-García JG; Palao M; Romero-Sánchez CM; Segura T
Mult Scler Relat Disord; 2020 Oct; 45():102402. PubMed ID: 32711297
[TBL] [Abstract][Full Text] [Related]
9. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L
Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745
[TBL] [Abstract][Full Text] [Related]
10. Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis.
Devogelaere J; D'hooghe MB; Vanderhauwaert F; D'haeseleer M
Neurol Sci; 2020 Aug; 41(8):1981-1983. PubMed ID: 32564270
[TBL] [Abstract][Full Text] [Related]
11. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
Louapre C; Maillart E; Roux T; Pourcher V; Bussone G; Lubetzki C; Papeix C
Rev Neurol (Paris); 2020 Jun; 176(6):523-525. PubMed ID: 32362357
[No Abstract] [Full Text] [Related]
12. A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.
Valencia-Sanchez C; Wingerchuk DM
Mult Scler Relat Disord; 2020 Jul; 42():102182. PubMed ID: 32416330
[TBL] [Abstract][Full Text] [Related]
13. MSCOVID19: Using social media to achieve rapid dissemination of health information.
Nesbitt C; Rath L; Yeh WZ; Zhong M; Wesselingh R; Monif M; Richards J; Minh VB; Jokubaitis VG; Skibina O; Butzkueven H; van der Walt A
Mult Scler Relat Disord; 2020 Oct; 45():102338. PubMed ID: 32629402
[TBL] [Abstract][Full Text] [Related]
14. Multiple sclerosis and COVID-19: A great opportunity for databases promoting research and collaboration.
Racke MK; Newsome SD
J Neuroimmunol; 2020 Aug; 345():577283. PubMed ID: 32518058
[No Abstract] [Full Text] [Related]
15. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 in MS: Initial observations from the Pacific Northwest.
Bowen JD; Brink J; Brown TR; Lucassen EB; Smoot K; Wundes A; Repovic P
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32457226
[No Abstract] [Full Text] [Related]
17. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
[TBL] [Abstract][Full Text] [Related]
18. Effects of MS disease-modifying therapies on responses to vaccinations: A review.
Ciotti JR; Valtcheva MV; Cross AH
Mult Scler Relat Disord; 2020 Oct; 45():102439. PubMed ID: 32769063
[TBL] [Abstract][Full Text] [Related]
19. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
Preziosa P; Rocca MA; Nozzolillo A; Moiola L; Filippi M
J Neurol; 2021 Aug; 268(8):2697-2699. PubMed ID: 33216223
[No Abstract] [Full Text] [Related]
[Next] [New Search]
